$VRXA

VERAXA Biotech AG (NASDAQ: VRXA) said it filed first BiTAC-related patent applications in H1 2026 covering its BiTAC-TCE and BiTAC-ADC platforms, including composition of matter and payload technologies. It also reported granted auxiliary patents clearing opposition. VERAXA has 50+ granted patents in 14 countries across 26 families, targeting protection through at least 2047.

VERAXA Biotech AG (NASDAQ: VRXA) said shareholders approved all proposals at an extraordinary general meeting. The vote passed with more than 99.94% approval, with 102,102,301 voting shares represented, or 72.20% of total share capital. Resolutions add conditional share capital, a capital band through Dec. 31, 2030, and expand the board from five to seven to support financing and strategic options.

VERAXA Biotech AG (NASDAQ: VRXA) appointed Christoph Erkel, Ph.D. as Chief Scientific Officer effective immediately. Erkel, previously VP of R&D, will lead development of the company’s BiTAC platform technologies for solid-tumor cancer therapies. He replaces Rick Austin, Ph.D., who will depart after a transition. The release cites Erkel’s 20 years in antibody therapeutics.

VERAXA Biotech AG (NASDAQ: VRXA) said it will launch an AI-enabled drug discovery collaboration with Ardigen S.A. to support VERAXA’s BiTAC pipeline of T cell engagers and future BiTAC-ADCs. The work will focus on AI tools to select synergistic cancer target pairs using dual-target “AND-gate” activation, aiming to improve oncology development decisions.

VERAXA Biotech AG (NASDAQ: VRXA) appointed Carl von Halem as interim CFO, effective immediately, succeeding Torsten Bürgermeister. The company said it is in the final stages of discussions with a successor and will update the market later. The release cites von Halem’s prior CFO role at Xlife Science and other life-sciences experience.

VERAXA Biotech AG (NASDAQ: VRXA) appointed Carl von Halem as interim CFO, replacing Torsten Bürgermeister. The company said it is in the final stages of talks with a successor and will update the market later. The release cites von Halem’s prior CFO role at Xlife Sciences and other life-sciences finance experience.

Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG

VERAXA Biotech AG (Nasdaq: VRXA) said it began cell line development for its lead BiTAC T-cell engager program, working with ATUM to use proprietary technology to generate stable clonal cell lines. VERAXA linked the step to prior encouraging preclinical results presented at AACR.

VERAXA Biotech AG (NASDAQ: VRXA) said it has started cell line development for its lead BiTAC® T-cell engager (BiTAC-TCE) program with ATUM using ATUM’s Leap-In Transposase® technology. The work aims to generate stable clonal lines for CMC and nonclinical material as the candidate moves toward IND/CTA-enabling activities.

VERAXA Biotech AG (NASDAQ: VRXA) said it has started cell line development for its lead BiTAC-TCE cancer therapy program with ATUM using ATUM’s Leap-In Transposase® technology. The work is intended to generate stable clonal cell lines for CMC and nonclinical supply, supporting IND/CTA-enabling activities after April AACR preclinical data.